Pyoderma gangrenosum - Gangrenos Pioderma
Gangrenos pioderma (Pyoderma gangrenosum) yra reta uždegiminė odos liga, kai skausmingos pūslelės ar mazgeliai virsta opomis, kurios palaipsniui auga. Gangrenos pioderma (Pyoderma gangrenosum) nėra užkrečiamas. Gydymas gali apimti kortikosteroidus, ciklosporiną arba įvairius monokloninius antikūnius. Nors liga gali pasireikšti bet kokio amžiaus žmonėms, dažniausiai ji pasireiškia 40–50‑metų amžiaus grupėje.
☆ AI Dermatology — Free Service
2022 m. Stiftung Warentest iš Vokietijos rezultatai rodo, kad vartotojų pasitenkinimas ModelDerm buvo tik šiek tiek mažesnis nei mokamų nuotolinės medicinos konsultacijų.
2022 m. Stiftung Warentest iš Vokietijos rezultatai rodo, kad vartotojų pasitenkinimas ModelDerm buvo tik šiek tiek mažesnis nei mokamų nuotolinės medicinos konsultacijų.
Ant opų, kolitu sergančio žmogaus kojos.
relevance score : -100.0%
ReferencesPyoderma gangrenosum yra reta odos liga, sukelianti skausmingas opas raudonais arba purpuriniais kraštais. Tai klasifikuojama kaip uždegiminė liga ir priklauso grupei, vadinama neutrofilinėmis dermatozėmis. Pyoderma gangrenosum priežastis yra sudėtinga, apimanti tiek įgimto, tiek adaptacinio imuniteto problemas žmonėms, kurie yra genetiškai linkę. Pastaruoju metu mokslininkai sutelkė dėmesį į plaukų folikulą kaip galimą ligos pradžios tašką.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum yra reta odos liga, sukelianti itin skausmingas opas. Nors mes visiškai nesuprantame jos priežasties, žinome, kad tai susiję su padidėjusiu tam tikrų imuninių ląstelių aktyvumu. Išgydyti ligą vis dar nėra lengva. Turime įvairių vaistų, kurie slopina imuninę sistemą arba modifikuoja jos veiklą. Be to, skiriame daug dėmesio žaizdų gydymui ir skausmo valdymui. Kortikosteroidai ir ciklosporinas dažnai yra pirmasis gydymo pasirinkimas, tačiau pastaruoju metu atlikti tyrimai, susiję su biologinės terapijos, pvz. TNF‑α inhibitorių, naudojimu, rodo didėjantį jų pranašumą, ypač pacientams, sergantiems kitomis uždegiminėmis ligomis, ir jie naudojami ankstyvame ligos etape.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
